IPM Take
An infection can be common and still remain politically invisible.
Gonorrhoea is often discussed through stigma, morality or individual behaviour. That framing misses the system failure. When testing is unaffordable, confidential services are hard to reach and surveillance is patchy, the infection does not vanish. It simply becomes easier for institutions not to count.
Executive Summary
A systematic review and meta-analysis published in PLOS Medicine in June 2026 synthesised nearly 1,000 publications and more than 1,600 gonorrhoea prevalence measures from sub-Saharan Africa between 1964 and 2025. The pooled prevalence estimate in the general population was approximately 3%, with substantially higher prevalence in some key populations, including female sex workers, men who have sex with men, and people attending STI clinics or presenting with symptoms. The authors found a gradual decline over time, but persistent high burden and major variation across countries, groups and anatomical sites.
Why it matters
- Public authorities: Need surveillance systems that reflect who is actually affected, not only who can access testing.
- Clinicians: Need confidential, stigma-aware diagnostic and treatment pathways that make early care easier.
- Patients / advocates: Need services designed around privacy, affordability and trust, rather than assumptions about who will come forward.
The most dangerous phrase in sexual health is often, “We do not have the data.”
Sometimes that means there is little transmission. More often, it means there is little testing.
The new analysis offers the clearest synthesis yet of gonorrhoea prevalence across sub-Saharan Africa. It finds that prevalence has declined gradually over decades, but remains substantial and unevenly distributed. The burden is higher in younger populations and in groups already facing more barriers to respectful, confidential care.
That is where the human story sits. A person may avoid a clinic because of cost, distance, shame, fear of being recognised or fear of judgment. A service may lack reliable diagnostic tools. A country may only have data from a small number of clinics, cities or study populations. Each gap makes the disease look smaller than it is.
Gonorrhoea is also becoming harder to treat as antimicrobial resistance grows. The study’s authors argue for stronger prevention, expanded testing and better surveillance systems. They also caution that evidence remains heterogeneous, with uneven data by country, population and infection site.
That limitation is not a reason to downgrade the problem. It is part of the problem.
For IPM, this is a diagnostic-access story before it is a treatment story. The right test, in the right place, with confidentiality and a route to care, is the difference between an infection being treated early and an infection being passed on, missed or recorded only years later in a research paper.
